Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Detalles Bibliográficos
Autores principales: Hortobagyi, G N, Stemmer, S M, Burris, H A, Yap, Y S, Sonke, G S, Paluch-Shimon, S, Campone, M, Petrakova, K, Blackwell, K L, Winer, E P, Janni, W, Verma, S, Conte, P, Arteaga, C L, Cameron, D A, Mondal, S, Su, F, Miller, M, Elmeliegy, M, Germa, C, O’Shaughnessy, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Corrigenda
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927326/
https://www.ncbi.nlm.nih.gov/pubmed/31407010
http://dx.doi.org/10.1093/annonc/mdz215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927326/
https://www.ncbi.nlm.nih.gov/pubmed/31407010
http://dx.doi.org/10.1093/annonc/mdz215

Ejemplares similares